| Target Price | $23.97 |
| Price | $17.00 |
| Potential |
41.00%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Immunome Inc 2026 .
The average Immunome Inc target price is $23.97.
This is
41.00%
register free of charge
$39.90
134.71%
register free of charge
$18.18
6.94%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Immunome Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Immunome Inc stock has an average upside potential 2026 of
41.00%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.04 | 7.69 |
| 35.52% | 14.92% | |
| EBITDA Margin | -1,674.23% | -2,625.93% |
| 738.31% | 56.84% | |
| Net Margin | -3,240.71% | -2,471.09% |
| 325.38% | 23.75% |
13 Analysts have issued a sales forecast Immunome Inc 2025 . The average Immunome Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Immunome Inc EBITDA forecast 2025. The average Immunome Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Immunome Inc Analysts have issued a net profit forecast 2025. The average Immunome Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.00 | -2.18 |
| 7.06% | 56.40% | |
| P/E | negative | |
| EV/Sales | 157.55 |
14 Analysts have issued a Immunome Inc forecast for earnings per share. The average Immunome Inc EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 22 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 22 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Sep 05 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 20 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


